[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:kmt2a-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"KMT2A Gene",37,33,[8,16,23,30,37,44,50,56,62,68,74,80,86,92,98,104,110,116,122,128,134,140,146,152,158,164,170,176,182,188,194,200,206,212,219,225,231],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07053059","Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)",[12],"Phase 2","RECRUITING","2026-08-26T02:18:19.586423Z","2026-05-05T02:43:29.369796Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07059975","UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML",[20],"Early Phase 1","2026-08-26T02:17:22.949982Z","2026-05-05T02:43:29.190474Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05360160","A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine\u002FCedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)",[27],"Phase 1\u002FPhase 2","2026-08-26T02:18:01.700186Z","2026-05-05T02:43:29.040577Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT06440135","Ziftomenib Maintenance Post Allo-HCT",[34],"Phase 1","2026-08-26T02:18:23.582895Z","2026-05-05T02:43:28.881398Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":42,"content_modified":43},"NCT07007312","Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML",[41],"Phase 3","2026-08-26T02:19:11.399072Z","2026-05-05T02:43:28.658489Z",{"nct_id":45,"title":46,"phases":47,"status":13,"updated_at":48,"content_modified":49},"NCT06852222","A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)",[41],"2026-08-26T02:16:28.221034Z","2026-05-05T02:43:28.415866Z",{"nct_id":51,"title":52,"phases":53,"status":13,"updated_at":54,"content_modified":55},"NCT06152809","CIML NK Cells With Venetoclax for AML",[34],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT06177067","Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia",[34],"2026-08-26T02:19:29.119921Z","2026-05-05T02:43:27.978998Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT06287229","Phase Ib\u002FII Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed\u002FRefractory (R\u002FR) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab\u002FHCVAD-inotuzumab-blinatumomab",[27],"2026-08-26T02:16:26.411851Z","2026-05-05T02:43:27.836826Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT06222580","SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation",[34],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:27.620905Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT06448013","A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia",[34],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:27.592833Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT07223814","Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)",[41],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:27.476715Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT04811560","A Phase 1\u002F2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",[27],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.311203Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT06376162","Ziftomenib in Combination With Chemotherapy for Children With Relapsed\u002FRefractory Acute Leukemia",[34],"2026-08-26T02:19:02.550788Z","2026-05-05T02:43:27.310236Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT07011004","A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia",[34],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:27.130925Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT05735184","A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax\u002FAzacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML",[34],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:26.898008Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT06001788","Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[34],"2026-08-26T02:18:46.948970Z","2026-05-05T02:35:31.908076Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT06769490","Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia",[34],"2026-08-26T02:16:06.684983Z","2026-05-05T02:35:31.897093Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT05886049","A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated\u002FFLT3 Wildtype or MLL\u002FKMT2A Rearranged or NUP98 Alterations Disease",[34],"2026-08-26T02:19:05.360997Z","2026-07-05T05:32:16.737825Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT05848687","TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II",[27],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:29.336397Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT03013998","Study of Biomarker-Based Treatment of Acute Myeloid Leukemia",[27],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.183972Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT07270978","Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS",[34],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.951482Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT06575296","Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant",[34],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:27.843378Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT07155226","Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression",[27],"2026-08-26T02:15:17.167444Z","2026-05-05T02:43:27.256920Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT07356154","A Study of Revumenib and Mezigdomide in People With Leukemia",[27],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:26.921862Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT07566377","Cord Blood Transplantation in Children and Young Adults With Blood Cancer",[12],"2026-08-26T02:15:09.079045Z","2026-05-13T02:55:06.730274Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT03826992","Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia",[34],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:29.669276Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT04099966","AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha\u002FBeta T Cell and CD19+ B Cell Depletion",[12],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:28.713058Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT04065399","A Study of Revumenib in R\u002FR Leukemias Including Those With an MLL\u002FKMT2A Gene Rearrangement or NPM1 Mutation",[27],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:27.111185Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":192,"content_modified":193},"NCT06397027","A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias",[34],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:27.100920Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":198,"content_modified":199},"NCT04726241","The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study",[27],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:29.704606Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT06652438","Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML",[41],"2026-08-26T02:18:21.216897Z","2026-07-30T01:46:14.441939Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT03016806","Umbilical Cord Blood Transplantation From Unrelated Donors",[],"2026-08-26T02:15:21.365312Z","2026-05-13T02:55:06.119599Z",{"nct_id":213,"title":214,"phases":215,"status":216,"updated_at":217,"content_modified":218},"NCT07605949","Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:15.642947Z","2026-05-29T15:36:40.223595Z",{"nct_id":220,"title":221,"phases":222,"status":216,"updated_at":223,"content_modified":224},"NCT07355335","Ziftomenib + Mezigdomide in Adolesc. and Adults w\u002F R\u002FR AML",[34],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:29.582690Z",{"nct_id":226,"title":227,"phases":228,"status":216,"updated_at":229,"content_modified":230},"NCT06930352","Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy",[12],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:29.137362Z",{"nct_id":232,"title":233,"phases":234,"status":216,"updated_at":235,"content_modified":236},"NCT07283640","A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia",[34],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:27.646903Z"]